Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study
Christina Fotopoulou(Ovarian Cancer Action), Hani Gabra(Royal Children's Hospital), Sharad Ghamande(Augusta University Health), J.A. Green(University of Liverpool), Mariusz Bidziński, Stuart Kaye(University of Wollongong), Ignace Vergote(KU Leuven), Sarah P. Blagden(Churchill Hospital), Paul R. Harnett(The University of Sydney), Jonathan A. Ledermann(London Cancer), Jan B. Vermorken(University of Antwerp), Marek Spaczyński(Poznan University of Medical Sciences), Salvatore A. Del Prete(Stamford Hospital), Martin Gore(Imperial College London), Paul N. Mainwaring(Australasia Paediatric Endocrine Group)
Cited by 38
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k